Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:AKBA's Cash-to-Debt is ranked higher than
75% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. NAS:AKBA: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AKBA' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: 12424.6
Current: No Debt
No Debt
12424.6
Equity-to-Asset 0.40
NAS:AKBA's Equity-to-Asset is ranked lower than
75% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NAS:AKBA: 0.40 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AKBA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.12  Med: 0.3 Max: 0.45
Current: 0.4
0.12
0.45
Interest Coverage No Debt
NAS:AKBA's Interest Coverage is ranked higher than
69% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:AKBA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:AKBA' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 0.45
Beneish M-Score: 1.05
WACC vs ROIC
14.54%
32.44%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -32.67
NAS:AKBA's Operating Margin % is ranked higher than
62% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. NAS:AKBA: -32.67 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AKBA' s Operating Margin % Range Over the Past 10 Years
Min: -8889.9  Med: -4467.4 Max: -32.67
Current: -32.67
-8889.9
-32.67
Net Margin % -30.60
NAS:AKBA's Net Margin % is ranked higher than
62% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. NAS:AKBA: -30.60 )
Ranked among companies with meaningful Net Margin % only.
NAS:AKBA' s Net Margin % Range Over the Past 10 Years
Min: -8843.45  Med: -4443.33 Max: -30.6
Current: -30.6
-8843.45
-30.6
ROE % -53.46
NAS:AKBA's ROE % is ranked lower than
57% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. NAS:AKBA: -53.46 )
Ranked among companies with meaningful ROE % only.
NAS:AKBA' s ROE % Range Over the Past 10 Years
Min: -136.35  Med: -82.06 Max: -51.66
Current: -53.46
-136.35
-51.66
ROA % -18.02
NAS:AKBA's ROA % is ranked higher than
66% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. NAS:AKBA: -18.02 )
Ranked among companies with meaningful ROA % only.
NAS:AKBA' s ROA % Range Over the Past 10 Years
Min: -365.24  Med: -56.06 Max: -18.02
Current: -18.02
-365.24
-18.02
ROC (Joel Greenblatt) % -2102.25
NAS:AKBA's ROC (Joel Greenblatt) % is ranked lower than
67% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. NAS:AKBA: -2102.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AKBA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -106220  Med: -16403.47 Max: -2102.25
Current: -2102.25
-106220
-2102.25
3-Year EBITDA Growth Rate 9.50
NAS:AKBA's 3-Year EBITDA Growth Rate is ranked higher than
56% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. NAS:AKBA: 9.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:AKBA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -63.4  Med: 9.5 Max: 51.7
Current: 9.5
-63.4
51.7
3-Year EPS without NRI Growth Rate 39.60
NAS:AKBA's 3-Year EPS without NRI Growth Rate is ranked higher than
84% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. NAS:AKBA: 39.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:AKBA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -40.1  Med: 39.6 Max: 56.5
Current: 39.6
-40.1
56.5
GuruFocus has detected 2 Warning Signs with Akebia Therapeutics Inc NAS:AKBA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AKBA's 30-Y Financials

Financials (Next Earnings Date: 2018-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

AKBA Guru Trades in Q3 2017

Caxton Associates 12,500 sh (New)
Chuck Royce 247 sh (New)
Jim Simons 1,420,900 sh (+38.58%)
Paul Tudor Jones Sold Out
» More
Q4 2017

AKBA Guru Trades in Q4 2017

Pioneer Investments 2,700 sh (New)
Chuck Royce 347 sh (+40.49%)
Jim Simons 1,821,200 sh (+28.17%)
Caxton Associates Sold Out
» More
Q1 2018

AKBA Guru Trades in Q1 2018

Steven Cohen 194,150 sh (New)
Paul Tudor Jones 21,105 sh (New)
Chuck Royce 537 sh (+54.76%)
Jim Simons 2,519,100 sh (+38.32%)
Pioneer Investments Sold Out
» More
Q2 2018

AKBA Guru Trades in Q2 2018

Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Chuck Royce Sold Out
Jim Simons 1,874,600 sh (-25.58%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:AKBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:OBSV, SZSE:002898, NAS:BCRX, NAS:AGEN, NAS:EDGE, OSTO:WTX, NAS:CNCE, XKRX:141080, LSE:OXB, BSP:GBIO33, LSE:PRTC, TSX:TH, NAS:SVA, NAS:ACHN, NAS:KERX, OSTO:CAMX, NAS:CDXS, NAS:MNOV, OCSE:ZEAL, XKRX:144510 » details
Traded in other countries:AX9.Germany,
Headquarter Location:USA
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology.

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.

Ratios

vs
industry
vs
history
PB Ratio 2.89
AKBA's PB Ratio is ranked higher than
76% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. AKBA: 2.89 )
Ranked among companies with meaningful PB Ratio only.
AKBA' s PB Ratio Range Over the Past 10 Years
Min: 2.28  Med: 5.96 Max: 18.08
Current: 2.89
2.28
18.08
PS Ratio 1.95
AKBA's PS Ratio is ranked higher than
88% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AKBA: 1.95 )
Ranked among companies with meaningful PS Ratio only.
AKBA' s PS Ratio Range Over the Past 10 Years
Min: 1.72  Med: 7.48 Max: 265
Current: 1.95
1.72
265
EV-to-EBIT -1.20
AKBA's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. AKBA: -1.20 )
Ranked among companies with meaningful EV-to-EBIT only.
AKBA' s EV-to-EBIT Range Over the Past 10 Years
Min: -5.4  Med: -1.8 Max: -0.4
Current: -1.2
-5.4
-0.4
EV-to-EBITDA -1.21
AKBA's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. AKBA: -1.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
AKBA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.5  Med: -1.8 Max: -0.4
Current: -1.21
-5.5
-0.4
EV-to-Revenue 0.39
AKBA's EV-to-Revenue is ranked higher than
99% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. AKBA: 0.39 )
Ranked among companies with meaningful EV-to-Revenue only.
AKBA' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.2  Med: 4.3 Max: 94.7
Current: 0.39
0.2
94.7
Current Ratio 2.48
AKBA's Current Ratio is ranked lower than
65% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. AKBA: 2.48 )
Ranked among companies with meaningful Current Ratio only.
AKBA' s Current Ratio Range Over the Past 10 Years
Min: 0.46  Med: 8.89 Max: 26.43
Current: 2.48
0.46
26.43
Quick Ratio 2.48
AKBA's Quick Ratio is ranked lower than
62% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. AKBA: 2.48 )
Ranked among companies with meaningful Quick Ratio only.
AKBA' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 8.89 Max: 26.43
Current: 2.48
0.46
26.43
Days Sales Outstanding 0.22
AKBA's Days Sales Outstanding is ranked higher than
50% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. AKBA: 0.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
AKBA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.22  Med: 4056.39 Max: 8042.6
Current: 0.22
0.22
8042.6

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -32.70
AKBA's 3-Year Average Share Buyback Ratio is ranked lower than
76% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. AKBA: -32.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AKBA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -319.9  Med: -32.7 Max: -26.1
Current: -32.7
-319.9
-26.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.18
AKBA's Price-to-Net-Cash is ranked higher than
82% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. AKBA: 3.18 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AKBA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.02  Med: 3.41 Max: 15.33
Current: 3.18
2.02
15.33
Price-to-Net-Current-Asset-Value 3.08
AKBA's Price-to-Net-Current-Asset-Value is ranked higher than
87% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. AKBA: 3.08 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AKBA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.99  Med: 3.32 Max: 13.53
Current: 3.08
1.99
13.53
Price-to-Tangible-Book 2.95
AKBA's Price-to-Tangible-Book is ranked higher than
82% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. AKBA: 2.95 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AKBA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.98  Med: 3.22 Max: 11.68
Current: 2.95
1.98
11.68
Price-to-Median-PS-Value 0.25
AKBA's Price-to-Median-PS-Value is ranked higher than
91% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. AKBA: 0.25 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AKBA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.14 Max: 33.58
Current: 0.25
0.24
33.58
Earnings Yield (Greenblatt) % -81.26
AKBA's Earnings Yield (Greenblatt) % is ranked lower than
92% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. AKBA: -81.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AKBA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -237.8  Med: -55.35 Max: -18.4
Current: -81.26
-237.8
-18.4

More Statistics

Revenue (TTM) (Mil) $223.32
EPS (TTM) $ -1.23
Beta1.90
Volatility41.19%
52-Week Range $7.32 - 18.39
Shares Outstanding (Mil)57.05

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 203 170 39 79
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -2.12 -1.23 -1.20 -0.39
EPS without NRI ($) -2.12 -1.23 -1.20 -0.39
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}